MedPath

Avascular Necrosis (AVN) Long-Term Follow-up

Terminated
Conditions
Avascular Necrosis
Femoral Head Collapse
Registration Number
NCT00833430
Lead Sponsor
Zimmer Biomet
Brief Summary

Long-term follow-up of IDE patients for publication

Detailed Description

This device (Hedrocel AVN Intervention Implant) was approved via 510(k) on April 15, 2005. One site was left open to follow patients to 5 year follow-up for publication of device survivorship.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
35
Inclusion Criteria
  • Patient qualifies for core decompression based on physical exam
  • No history of core decompression
  • Patient is willing and able to provide written informed consent
Exclusion Criteria
  • Patient has been diagnosed as Stage 0, III, IV, V or VI using the Steinberg/UPenn staging system.
  • Patient's BMI is >40
  • Patient is mentally compromised
  • Patient has neurological condition in ipsilateral or contralateral limb, which affect lower limb function
  • The patient has had a proximal femoral osteotomy or internal fixation in the affected hip.
  • The patient has undergone previous treatment for AVN
  • Previous hip conditions
  • Patient's bone stock is insufficient
  • Patient has diagnosed systemic disease
  • Patient is a pregnant female
  • Patient is unable or unwilling to attend postop follow-up visits
  • Patient has received investigational drug within the previous 6 months or an investigational device within the last 12 months
  • Patient has an active or latent infection
  • Patient has metal sensitivity
  • Patient is a prisoner

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Safety, Efficacy and longevity of device with patient as opposed to conventional total hip replacement5 Year Follow-up
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Emory Orthopedic Clinic

🇺🇸

Atlanta, Georgia, United States

© Copyright 2025. All Rights Reserved by MedPath